In this capacity, Integral Biosystems, LLC has already attended the Society for Biomaterials 2011 and the ARVO 2011 meetings, held in April and May, 2011. Integral BioSystems intends to attend the AAPS conference in Oct, 2011.
The company specializes in the design and development of dosage forms for ophthalmic, transdermal, intravenous, intranasal and oral routes of drug administration. Furthermore, the company offers intellectual property and contracts development/
About Integral BioSystems, LLC
Integral BioSystems, LLC was founded in 2008 by experienced drug development and patent professionals. The company has adopted a translational medicinal approach to drug development, customizing delivery systems to accomplish the biologically effective objectives of the therapy. Delivery systems are customized to achieve sustained release or targeted, tissue-focused delivery, or fast-release/
Once the drug-containing formulations are tested in preclinical models, an integrated CMC plan is developed to systematically transition the project to scale up and product development. As part of product development, Integral BioSystems specializes in efficiently developing a dosage form to manufacture and test in Phase I/Phase II first-in-man trials for proof-of-concept. The company has a network of manufacturers / analytical houses for pharmaceutics, that can fast-track the manufacture and release of the sterile dosage form for first-in-man trials.
Contact:
David Karasic
Chief Intellectual Property and Business Development Officer
Integral BioSystems, LLC
781-879-4677
# # #
A boston area-based contract research organization, Integral BioSystems specializes in the development of ophthalmic, transdermal, intravenous, intranasal and oral dosage forms. Additionally, we offer services in intellectual property and contracts.
